Catalent traded at $63.49 this Tuesday December 17th, increasing $0.02 or 0.02 percent since the previous trading session. Looking back, over the last four weeks, Catalent gained 8.03 percent. Over the last 12 months, its price rose by 51.56 percent. Looking ahead, we forecast Catalent to be priced at 61.54 by the end of this quarter and at 56.05 in one year, according to Trading Economics global macro models projections and analysts expectations.
Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.